|Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.||MD, CEO & Director||529.1k||N/A||1960|
|Mr. Jeff Carter BFinAdmin, MAppFin||Chief Financial Officer||112.8k||N/A||1958|
|Ms. Tamara Miller||Sr. VP of Product Devel.||406.56k||N/A||N/A|
|Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.||Chief Medical Officer||164.02k||N/A||N/A|
|Mr. Michael Roberts||Head of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Therese Russell||Head of People & Infrastructure||N/A||N/A||N/A|
|Dr. Christian Toouli||Head of Bus. Devel.||N/A||N/A||N/A|
|Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD||Company Sec.||N/A||N/A||1963|
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Actinogen Medical Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.